A phase III study of NF-kappa-B-Decoy for the treatment for atopic dermatitis (AD) in Japan

Trial Profile

A phase III study of NF-kappa-B-Decoy for the treatment for atopic dermatitis (AD) in Japan

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Jul 2016

At a glance

  • Drugs NF kappa B Decoy-AnGes MG (Primary)
  • Indications Atopic dermatitis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors AnGes MG
  • Most Recent Events

    • 05 Jul 2016 Primary endpoint (Improvement in the dermatological scores at week 4) was not met, according to an AnGes MG media release.
    • 05 Jul 2016 Top-line results published in an AnGes MG media release.
    • 19 Jan 2016 According to AnGes media release, if this study gives favourable results than company will submit an application for drug marketing approval in Japan for the indication of moderate to severe facial atopic dermatitis.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top